MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Начало・Списък с акции・Omeros Corp

Omeros Corp

Затворен

СекторЗдравеопазване

7.07 -3.81

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.04

Максимум

7.47

Ключови измерители
By Trading Economics
Приходи	24M -32M
EPS	-0.55
Служители	198
EBITDA	-33M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+249.32% upside

Дивиденти
By Dow Jones
Следващи печалби	14.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	275M 491M
Предишно отваряне	10.88
Предишно затваряне	7.07

Настроения в новините

By Acuity

40%

60%

124 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 9.16 Подкрепа & съпротива

Omeros Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4.04.2025 г., 21:53 ч. UTC

Пазарно говорене

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4.04.2025 г., 21:44 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4.04.2025 г., 21:00 ч. UTC

Топ новини

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4.04.2025 г., 20:52 ч. UTC

Пазарно говорене

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4.04.2025 г., 20:52 ч. UTC

Топ новини

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.04.2025 г., 20:48 ч. UTC

Топ новини

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4.04.2025 г., 20:45 ч. UTC

Топ новини

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4.04.2025 г., 20:32 ч. UTC

Топ новини

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4.04.2025 г., 20:21 ч. UTC

Топ новини

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4.04.2025 г., 20:00 ч. UTC

Топ новини

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4.04.2025 г., 19:51 ч. UTC

Пазарно говорене

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4.04.2025 г., 19:37 ч. UTC

Топ новини

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4.04.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4.04.2025 г., 19:28 ч. UTC

Топ новини

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4.04.2025 г., 19:15 ч. UTC

Пазарно говорене

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4.04.2025 г., 19:12 ч. UTC

Топ новини

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4.04.2025 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Пазарно говорене

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Топ новини

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4.04.2025 г., 19:00 ч. UTC

Пазарно говорене

Fed Has Limited Options to Counter Tariffs -- Market Talk

4.04.2025 г., 18:53 ч. UTC

Пазарно говорене

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4.04.2025 г., 18:51 ч. UTC

Пазарно говорене

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4.04.2025 г., 18:39 ч. UTC

Пазарно говорене

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Omeros Corp Прогноза

Ценова цел

By TipRanks

249.32% нагоре

12-месечна прогноза

Среден 25.71 USD 249.32%

Висок 45 USD

Нисък 6.418 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Omeros Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Omeros Corp през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 9.16Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

124 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.